The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Cleaner - you obviously have no idea how many companies Genmab are working with. To think that they are recruiting for senior postions in their organisation with direct relevance to Scancell is ludicrous. It is just general recruitment, the same as any other large pharma recruit all the time - should we post all their vacancies too? However I’ll give you 10 out of 10 for imagination.
With respect, I don’t understand the relevance to Scancell of these jobs at Genmab. Of course I understand they are evaluating a Scancell product but the fact they are recruiting for Director roles in their wider organisation, carries no relevance whatsoever to that in my opinion.
Agreed Chester. I also think that the picture here often gets very clouded by constant reference to investments made 10+ years ago. Not suggesting at all that isn’t factually correct for some posters but it’s also a hard fact that it’s less than 4 years since Redmile liked what they saw and fully backed the company with the cash needed to accelerate progress in the clinic.
I guess some folk just love to whinge!
https://www.youtube.com/watch?v=ZqLT3PmOKtQ
There are many, globally.
In the UK, Bowers Group springs to mind.
Interesting read from the Industrial Vision Systems website:
https://www.industrialvision.co.uk/news/catalysts-of-change-how-robots-machine-vision-and-ai-are-changing-the-automotive-manufacturing-landscape
An Oxford Metrics acquisition in the AI sweetspot.
IMO, it won’t be a case of either MRNA, or DNA as an available treatment option and there will be room for both as ammo against melanoma. In the same way that there are often multiple treatment options for other diseases. Assuming of course that trial data proves they both work well.
The publicity is positive on a number of fronts. Scancell now need to get their own data published. We already know that should be this year and we’re already in April, so it’s just a handful of months away.
Schlum - doubt it.
From the AGM Statement made in January:
“Trading is in-line with expectations. Further information on trading will be provided when interim results for the six months ending 31 March 2024 are announced”
Interims will be in June.